Chimeric antigen receptor (CAR) T cell therapy targeting CA19-9, an antigen over-expressed in several cancers, including 80-90% of pancreatic cancers.
A flexible toolkit for human gene editing, activation, and repression that can be applied in orthogonally and in various disease models.
A method to combine two or three monoclonal antibodies (mABs) into one treatment to successfully bind to multiple cancer cell surface epitopes and promote targeted degradation by phagocytosis.
Antigen-specific immunotherapy with engineered cytotoxic T cells targeting misformed proteins to treat neurodegenerative and muscular diseases.
Synergistic combination of mechanoporation and lipid nanoparticle (LNP) based transfection for an efficient, non-viral method of gene transfer to generate CAR-T cell therapies.
Short, multivalent peptide antagonists to block macrophage immune-receptor SIRPα, promoting cancer cell phagocytosis.
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications.
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity).
Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties.
A method that maintains the viability and function of NK cells following cryopreservation, enabling the production, storage, and transportation of therapeutic doses of NK cells to treatment centers.